Verisense Health, a spin-off from Shimmer Research

Verisense® Health, Inc., launched today, is a digital health software and data management company. It was established to provide sponsors with cost-effective access to digital biobanks of longitudinal raw patient data. The new company is a spin-out from Shimmer Research, a Dublin-based manufacturer of wearable technology services and sensors.

“Several factors drove the launch of Verisense Health. Shimmer Research touches many markets, but as an independent company, Verisense Health can focus all its attention on digital health, and software development to scale faster. Our customer support will also be more focused. Shimmer Research will continue to supply Verisense Health with wearable sensors. However, Verisense Health will also purchase sensors and other digital health technology from third-party suppliers ,” said Geoffrey Gill, CEO of Verisense Health.

Verisense Health will be the sole marketer of the modular Verisense wearable sensor platform, which Shimmer Research has developed from the ground up for use in clinical trials and remote patient studies. Going forward, the Verisense platform will be open to non-Shimmer Research hardware. Verisense Health will also take ownership of the Verisense Digital Health Panel (DHP), launching in 2022 to provide clinical researchers with access to raw, real-world, digital health ground-truth sensor data.

Verisense DHP is recruiting clinical study participants and healthy volunteers for its Institutional Review Board (IRB) approved longitudinal study. Participants contribute their medical histories, wearable sensor data, and monthly survey data to Verisense DHP. This data can be combined with patient-reported outcomes and real-world data, including tokenized medical records, claims data, and pharmacy records, to provide a complete longitudinal view of participant health.

“Our Verisense Digital Health Panel infrastructure enables us to be an extremely cost-effective digital health data collector for existing clinical trials, turnkey studies and companion studies. By bringing together all raw data in one place, we are Build a digital biobank that will enable researchers to conduct future scientific research without the need to collect new data. Our clients will benefit from access to low-cost, low-burden digital health data collection services, best-in-class digital health technology, and the ever-growing database of raw digital health data and associated outcomes – both patient-reported and real-world data. Customers only pay for the data delivered, not hardware, software and specific services,” added Mr Gill road.

Verisense Health’s initial focus will be on brain health, including Alzheimer’s disease, bipolar disorder and Parkinson’s disease, but its approach is applicable to virtually any indication.

The majority of Shimmer Research employees focused on clinical research in Boston, Malaysia and Dublin will join Verisense Health. Shimmer Research will also provide initial funding, marketing, management and quality control support to Verisense Health. However, the new company is expected to be fully independent within three to six months. Financial information about the transaction was not disclosed.

For more information on Verisense Health, its Verisense platform and the Verisense Digital Health Panel, visit www.verisense.net.

About Verisense Health

Verisense Health is a digital health software and data management company. The company is using its Verisense wearable sensor platform and Verisense Digital Health Panel to create a digital biobank that researchers can use to conduct digital health research without collecting new patient data. The company is headquartered in Cambridge, Massachusetts, with offices in Malaysia. For more information, visit www.verisense.net, www.linkedin.com/company/verisense-health or www.facebook.com/VerisenseHealth.